✨
AI Summary
- Amylyx withdraws Relyvrio post-trial failure, potentially inspiring more pledges.
- FDA considers bringing allergy/asthma biomarkers to advisory committees.
- Japan's PMDA opens an office in Washington D.C.
Citeline Podcasts